PARIS — The early commercial experience with transcatheter aortic valve replacement (TAVR or TAVI) for severe aortic regurgitation appeared promising, though device size issues and conduction disturbance risk leave room for improvement.
Performing TAVR with the Jenavalve Trilogy on 45 consecutive patients with severe aortic regurgitation, operators at German six centers achieved 100% technical success, defined as mean gradients